NRIX Nurix Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1549595 · Fiscal year ends 11/30
Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY738.8%
TTM net income YoY220.5%
TTM EPS YoY181.8%
Revenue 3-yr CAGR117.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin41.3%
Net margin42.0%
FCF margin52.7%
EBITDA margin42.5%
Returns
ROE44.0%
ROA34.3%
ROIC (approx.)84.5%
Asset turnover0.82x
Leverage & solvency
Liabilities / assets19.0%
Debt / equity0.00x
Current ratio8.44x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.29x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-08-31 | 2026Q22026-05-31 | 2026Q12026-02-28 | 2025Q4*2025-11-30 | 2025Q32025-08-31 | 2025Q22025-05-31 | 2025Q12025-02-28 | 2024Q4*2024-11-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $673.06M | $9.04M | $6.25M | $13.58M | $7.89M | $44.06M | $18.45M | $13.28M |
| R&D expense | $79.26M | $87.65M | $84.14M | $83.02M | $86.12M | $78.10M | $69.66M | $67.22M |
| SG&A expense | $34.35M | $15.59M | $14.61M | $13.65M | $13.16M | $14.28M | $11.65M | $10.72M |
| Operating income | $559.45M | -$94.20M | -$92.50M | -$83.09M | -$91.39M | -$48.32M | -$62.86M | -$64.66M |
| Pretax income | $563.41M | -$89.81M | — | -$78.22M | -$86.42M | -$42.70M | -$56.35M | -$58.54M |
| Income tax | $13.61M | -$271,000 | $0 | $0 | $0 | $760,000 | $0 | $8,000 |
| Net income | $549.81M | -$89.53M | -$87.17M | -$78.22M | -$86.42M | -$43.46M | -$56.35M | -$58.55M |
| EBITDA | $561.59M | -$91.95M | -$90.30M | -$80.97M | -$89.36M | -$46.08M | -$60.51M | -$62.11M |
| EPS (basic) | 4.93 | -0.81 | -0.79 | — | -1.03 | -0.52 | -0.67 | — |
| EPS (diluted) | 4.73 | -0.81 | -0.79 | — | -1.03 | -0.52 | -0.67 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 116.15M | 111.08M | 110.07M | — | 84.16M | 83.88M | 83.56M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $720.24M | $67.69M | $71.19M | $246.96M | $78.44M | $84.26M | $75.92M | $110.90M |
| Receivables | $20.00M | — | — | $0 | — | $19.00M | — | $0 |
| Current assets | $1.10B | $456.48M | $554.39M | $606.82M | $440.60M | $515.33M | $563.70M | $619.39M |
| PP&E, net | $19.41M | $20.01M | $21.70M | $22.49M | $20.50M | $18.77M | $18.45M | $17.76M |
| Total assets | $1.20B | $535.54M | $636.13M | $688.13M | $522.47M | $591.55M | $615.04M | $669.34M |
| Current liabilities | $130.74M | $72.02M | $92.20M | $86.47M | $82.35M | $75.61M | $89.99M | $95.85M |
| Total liabilities | $226.99M | $132.91M | $155.24M | $149.39M | $150.22M | $143.95M | $134.13M | $142.35M |
| Shareholders' equity | $968.31M | $402.63M | $480.89M | $538.75M | $372.25M | $447.60M | $480.92M | $526.99M |
| Shares outstanding | 109.20M | 103.70M | 103.40M | 101.81M | 76.87M | 76.43M | 76.23M | 75.87M |
| Cash flow statement | ||||||||
| Operating cash flow | $615.63M | -$96.57M | -$71.91M | -$67.83M | -$57.38M | -$63.16M | -$61.09M | -$48.75M |
| Capital expenditure | $1.39M | $1.94M | $1.04M | $5.13M | $2.71M | $2.67M | $3.48M | $2.10M |
| Free cash flow | $614.24M | -$98.51M | -$72.96M | -$72.96M | -$60.10M | -$65.84M | -$64.57M | -$50.86M |
| Investing cash flow | $31.58M | $93.00M | -$123.83M | $346,000 | $50.48M | $71.50M | $25.53M | -$140.82M |
| Financing cash flow | $5.16M | $66,000 | $19.98M | $236.01M | $1.16M | $6,000 | $1.47M | $200.52M |
| Depreciation & amortization | $2.14M | $2.25M | $2.20M | $2.12M | $2.03M | $2.24M | $2.35M | $2.55M |
| Stock-based compensation | $10.78M | $11.39M | $9.40M | $9.09M | $9.77M | $10.38M | $8.72M | $8.51M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.